853909-08-7Relevant articles and documents
Design of α7 nicotinic acetylcholine receptor ligands using the (het)Aryl-1,2,3-triazole core: Synthesis, in vitro evaluation and SAR studies
Ouach, Aziz,Pin, Frederic,Bertrand, Emilie,Vercouillie, Johnny,Gulhan, Zuhal,Mothes, Céline,Deloye, Jean-Bernard,Guilloteau, Denis,Suzenet, Franck,Chalon, Sylvie,Routier, Sylvain
, p. 153 - 164 (2015/11/18)
We report here the synthesis of a large library of 1,2,3-triazole derivatives which were in vitro tested as α7 nAchR ligands. The SAR study revealed that several crucial factors are involved in the affinity of these compounds for α7 nAchR such as a (R) quinuclidine configuration and a mono C-3 quinuclidine substitution. The triazole ring was substituted by a phenyl ring bearing small OMe/CH2F groups or fluorine atom and by several heterocycles such as thiophenes, furanes, benzothiophenes or benzofuranes. Among the 30 derivatives tested, the two derivatives 10 and 39 with Ki in the nanomolar range were identified (2.3 and 3 nM respectively). They exhibited a strict selectivity toward the α4β2 nicotinic receptor (up to 1 μM) but interacted with the 5HT3 receptors with Ki around 3 nM. Synthesis, SAR studies and a full description of the derivatives are reported.
1,4-DISUBSTITUTED 1,2,3-TRIAZOLES, METHODS FOR PREPARING SAME, AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF
-
Paragraph 0435; 0437, (2014/02/16)
A compound having the following general formula (I): wherein: X is a nitrogen atom and Y is a carbon atom; orX is a carbon atom and Y is a nitrogen atom;the Ar group is an aryl or heteroaryl group; andthe RN and RN′ groups, together with the carbon atoms
SUBSTITUTED ETHYNYL GOLD-NITROGENATED HETEROCYCLIC CARBENE COMPLEX AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME
-
Page/Page column 40, (2008/06/13)
The present invention provides a substituted ethynyl gold-nitrogen containing heterocyclic carbene complex represented by the general formula (1): wherein L represents a nitrogen containing heterocyclic carbene ligand; and X represents an alkyl group, a cycloalkyl group, an aryl group, an aralkyl group or a heterocyclic group; in which one or more hydrogen atoms on the carbon atom(s) of X may be replaced by a halogen atom, an alkyl group, a cycloalkyl group, an alkenyl group, an aryl group, an aralkyl group, an alkoxy group, an aryloxy group, a dialkylamino group, an acyl group or an arylcarbonyl group; and, when more than one hydrogen atom on the carbon atom(s) of X is replaced by the alkyl group, the alkenyl group, the aryl group, the aralkyl group, the alkoxy group, the aryloxy group, the dialkylamino group, the acyl group or the arylcarbonyl group, the adjacent groups may be bonded together to form a ring, a method for preparing the same, and an organic electroluminescent device comprising the substituted ethynyl gold-nitrogen containing heterocyclic carbene complex in at least one organic compound thin layer.
1H-IMIDAZO[4,5-C]QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES
-
Page/Page column 75, (2010/02/12)
The invention relates to the use of imidazoquinolines and salts thereof in the treatment of protein kinase diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases, imidazoquinolines for use in the treatment of protein kinase dependent diseases, a method of treatment against said diseases, comprising administering the imidazoquinolines to a warm-blooded animal, especially a human, pharmaceutical preparations comprising an imidazoquinoline, especially for the treatment of a protein kinase dependent disease, novel imidazoquinolines, and a process for the preparation of the novel imidazoquinolines.
